This quarterly report represents an earnings surprise of 9%. A quarter ago, it was expected that this drug developer would post earnings of $0.94 per share when it actually produced earnings of $1.09, delivering a surprise of 15.96%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. There are no easy answers to this key question, but one reliable measure that c ...